AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19691461 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of shingles
Number of subjects: 0
Study 19691461 — intervention group
Group type: EXPERIMENTAL
Intervention: Different classes of drugs for post-herpetic neuralgia
Number of subjects: 0
Study 17224202 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycaemic index cereal
Number of subjects: 64
Study 17224202 — intervention group
Group type: COMPARATOR
Intervention: High glycaemic index cereal
Number of subjects: 64
Study 15575055 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-embryo transfer
Number of subjects: 661
Study 15575055 — intervention group
Group type: COMPARATOR
Intervention: Single-embryo transfer
Number of subjects: 661
Study 11276371 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage (GM)-CSF
Number of subjects: 35
Study 11276371 — intervention group
Group type: COMPARATOR
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 35
Study 11276371 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF followed by G-CSF
Number of subjects: 35
Study 9389268 — intervention group
Group type: EXPERIMENTAL
Intervention: Colour kinesis
Number of subjects: 60
Study 9389268 — intervention group
Group type: COMPARATOR
Intervention: Conventional TOE method
Number of subjects: 60
Study 7947191 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 application of SPF 25 sunscreen
Number of subjects: 98
Study 7947191 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 applications of SPF 25 sunscreen
Number of subjects: 98
Study 7947191 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 applications of SPF 25 sunscreen
Number of subjects: 98
Study 3145357 — intervention group
Group type: EXPERIMENTAL
Intervention: VACA chemotherapy (vincristine, actinomycin D, cyclophosphamide, and adriamycin) with local control via surgery and/or radiation
Number of subjects: 93
Study 3145357 — intervention group
Group type: EXPERIMENTAL
Intervention: VAIA chemotherapy (high doses of ifosfamide with mesna uroprotection)
Number of subjects: 93
Study 3145357 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation or accelerated split‐course hyperfractionation (randomized for patients with radiation)
Number of subjects: 93
Study 30566760 — intervention group
Group type: COMPARATOR
Intervention: Curcumin (CUR) 180 mg/d for 7 days before exercise
Number of subjects: 10
Study 30566760 — intervention group
Group type: COMPARATOR
Intervention: Curcumin (CUR) 180 mg/d for 7 days after exercise
Number of subjects: 10
Study 29092078 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium selenite 300 µg/d po + Methimazole (MMI)
Number of subjects: 70
Study 29092078 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Methimazole (MMI)
Number of subjects: 70
Study 29092078 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium selenite + Methimazole (MMI)
Number of subjects: 70
Study 25307674 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg
Number of subjects: 54
Study 25307674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 23811682 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly purified eicosapentaenoic acid (EPA) 1,800 mg/day for 6 months
Number of subjects: 144
Study 23811682 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EPA treatment)
Number of subjects: 144
Study 19766643 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline laboratory tests and histologic data
Number of subjects: 1050
Study 18199388 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (2.9 g n-3 LCPUFA/d)
Number of subjects: 100
Study 18199388 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 100
Study 18199388 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 100
Study 15746685 — intervention group
Group type: EXPERIMENTAL
Intervention: Forceps delivery combined with mediolateral episiotomy
Number of subjects: 5377
Study 15746685 — intervention group
Group type: EXPERIMENTAL
Intervention: High birth weight
Number of subjects: 5377
Study 15746685 — intervention group
Group type: EXPERIMENTAL
Intervention: Episiotomy
Number of subjects: 5377
Study 15746685 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged first and second stages of labor
Number of subjects: 5377
Study 15746685 — intervention group
Group type: EXPERIMENTAL
Intervention: Low parity
Number of subjects: 5377
Study 12761604 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual academic detailing visits (2 visits on NSAIDs)
Number of subjects: 184
Study 12761604 — intervention group
Group type: EXPERIMENTAL
Intervention: Group academic detailing visits (2 visits during local quality group meetings)
Number of subjects: 184
Study 12761604 — intervention group
Group type: COMPARATOR
Intervention: Individual academic detailing visits
Number of subjects: 184
Study 12761604 — intervention group
Group type: COMPARATOR
Intervention: Group academic detailing visits
Number of subjects: 184
Study 10374155 — intervention group
Group type: EXPERIMENTAL
Intervention: Limbal approach for primary posterior capsulectomy and anterior vitrectomy
Number of subjects: 38
Study 10374155 — intervention group
Group type: COMPARATOR
Intervention: Pars plana approach for primary posterior capsulectomy and anterior vitrectomy
Number of subjects: 38
Study 9082343 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhosis of the liver
Number of subjects: 30
Study 9082343 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic active hepatitis (CAH)
Number of subjects: 30
Study 9082343 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 30
Study 1676932 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-458 (up to 60 mg per day)
Number of subjects: 19
Study 1676932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 1676932 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbidopa/levodopa
Number of subjects: 19
Study 6352636 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 28
Study 6352636 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin plus carbenicillin
Number of subjects: 28
Study 30762806 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g single dose of azithromycin
Number of subjects: 460
Study 30762806 — intervention group
Group type: COMPARATOR
Intervention: 100 mg doxycycline twice daily for 7 days
Number of subjects: 460
Study 30762806 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 460
Study 29180640 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII combined with metformin therapy
Number of subjects: 188
Study 29180640 — intervention group
Group type: COMPARATOR
Intervention: CSII therapy
Number of subjects: 188
Study 26913382 — intervention group
Group type: EXPERIMENTAL
Intervention: First-episode psychosis patients with nonauditory hallucinations
Number of subjects: 67
Study 26913382 — intervention group
Group type: COMPARATOR
Intervention: Control group without nonauditory hallucinations
Number of subjects: 67
Study 25060113 — intervention group
Group type: EXPERIMENTAL
Intervention: Water campaign intervention
Number of subjects: 1288
Study 20740300 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib (5 mg oral dose) with ketoconazole (400 mg/day for 7 days)
Number of subjects: 32
Study 20740300 — intervention group
Group type: COMPARATOR
Intervention: Axitinib (5 mg oral dose) alone
Number of subjects: 32
Study 19673008 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Referral‐‐4 outcalls
Number of subjects: 571
Study 19673008 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Referral‐‐1 outcall
Number of subjects: 571
Study 19673008 — intervention group
Group type: COMPARATOR
Intervention: Passive Referral (Control)
Number of subjects: 571
Study 18078888 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined sciatic nerve block and continuous '3-in-1' block with bupivacaine (group TS)
Number of subjects: 30
Study 18078888 — intervention group
Group type: COMPARATOR
Intervention: Continuous '3-in-1' block with bupivacaine (group T)
Number of subjects: 30
Study 16280277 — intervention group
Group type: EXPERIMENTAL
Intervention: UACR above the median value of 1.406
Number of subjects: 960
Study 16280277 — intervention group
Group type: EXPERIMENTAL
Intervention: AV sclerosis
Number of subjects: 960
Study 12011966 — intervention group
Group type: EXPERIMENTAL
Intervention: HR (Paroven-Venoruton; 0-(beta-hydroxyethyl)-rutosides) 2 g/day for 8 weeks
Number of subjects: 60
Study 12011966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10215707 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed-wave Doppler
Number of subjects: 45
Study 10215707 — intervention group
Group type: EXPERIMENTAL
Intervention: Transverse continuous-wave Doppler
Number of subjects: 45
Study 10215707 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal continuous-wave Doppler
Number of subjects: 45
Study 10215707 — intervention group
Group type: COMPARATOR
Intervention: Thermodilution technique
Number of subjects: 45
Study 8580948 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral eccentric weight training (8 weeks, 3 times per week, 3-5 sets of six repetitions)
Number of subjects: 17
Study 8580948 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral eccentric weight training
Number of subjects: 17
Study 8580948 — intervention group
Group type: EXPERIMENTAL
Intervention: Detraining (8 weeks after training)
Number of subjects: 17
Study 2395047 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 0
Study 2395047 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 0
Study 2395047 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 0
Study 2395047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 85988 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid (E.A.C.A.), 36 g/day
Number of subjects: 165
Study 85988 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antifibrinolytic drug)
Number of subjects: 165
Study 31957601 — intervention group
Group type: EXPERIMENTAL
Intervention: Appreciative Inquiry intervention
Number of subjects: 50
Study 31957601 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 31362109 — intervention group
Group type: EXPERIMENTAL
Intervention: aPDT with TBO+635 nm diode laser
Number of subjects: 80
Study 31362109 — intervention group
Group type: EXPERIMENTAL
Intervention: aPDT with ICG+808 nm diode laser
Number of subjects: 80
Study 31362109 — intervention group
Group type: EXPERIMENTAL
Intervention: TBO alone
Number of subjects: 80
Study 31362109 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 28121741 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus plus reduced-dose tacrolimus (EVR + rTAC)
Number of subjects: 211
Study 28121741 — intervention group
Group type: COMPARATOR
Intervention: Standard tacrolimus (TAC-C)
Number of subjects: 211
Study 26686042 — intervention group
Group type: EXPERIMENTAL
Intervention: COST measure (financial toxicity score range 0-44)
Number of subjects: 100
Study 23307042 — intervention group
Group type: EXPERIMENTAL
Intervention: LA group: lansoprazole (LPZ) 30 mg 4 times a day + amoxicillin (AMPC) 500 mg 4 times a day for two weeks
Number of subjects: 204
Study 23307042 — intervention group
Group type: EXPERIMENTAL
Intervention: LAL group: LPZ 30 mg twice a day + AMPC 750 mg twice a day + levofloxacin (LVFX) 300 mg twice a day for one week
Number of subjects: 204
Study 23307042 — intervention group
Group type: EXPERIMENTAL
Intervention: LAS group: LPZ 30 mg twice a day + AMPC 750 mg twice a day + sitafloxacin (STFX) 100 mg twice a day for one week
Number of subjects: 204
Study 21505377 — intervention group
Group type: COMPARATOR
Intervention: Booklet only
Number of subjects: 338
Study 21505377 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation only
Number of subjects: 338
Study 19340904 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 68
Study 19340904 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 68
Study 16525224 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy
Number of subjects: 0
Study 14741858 — intervention group
Group type: EXPERIMENTAL
Intervention: Students who received the names of stations prior to the OSCE (n=20)
Number of subjects: 60
Study 14741858 — intervention group
Group type: COMPARATOR
Intervention: Students who did not receive the names of stations prior to the OSCE (n=40)
Number of subjects: 60
Study 14741858 — intervention group
Group type: EXPERIMENTAL
Intervention: Students who received the names of stations prior to the OSCE
Number of subjects: 60
Study 14741858 — intervention group
Group type: COMPARATOR
Intervention: Students who did not receive the names of stations prior to the OSCE
Number of subjects: 60
Study 14741858 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 11108761 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Stroke Unit Service (ESUS)
Number of subjects: 320
Study 11108761 — intervention group
Group type: COMPARATOR
Intervention: Ordinary Stroke Unit Service (OSUS)
Number of subjects: 320
Study 9368828 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic use of ursodiol
Number of subjects: 0
Study 1375826 — intervention group
Group type: EXPERIMENTAL
Intervention: Grid laser treatment
Number of subjects: 1
Study 1375826 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 1
Study 3963846 — intervention group
Group type: EXPERIMENTAL
Intervention: Bestatin
Number of subjects: 101
Study 3963846 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 101
Study 27533623 — intervention group
Group type: EXPERIMENTAL
Intervention: ALC group
Number of subjects: 88
Study 27533623 — intervention group
Group type: COMPARATOR
Intervention: Non-ALC group
Number of subjects: 88
Study 27727241 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-current (DC) stimulation
Number of subjects: 45
Study 27727241 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency alternating-current (AC) stimulation
Number of subjects: 45
Study 27727241 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 45
Study 25924421 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 40
Study 25924421 — intervention group
Group type: COMPARATOR
Intervention: Reflexology
Number of subjects: 40
Study 22610178 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid-conservative therapy
Number of subjects: 931
Study 22610178 — intervention group
Group type: COMPARATOR
Intervention: Fluid-liberal therapy
Number of subjects: 931
Study 22610178 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in plasma angiopoietin-2 levels from day 0 to day 3
Number of subjects: 931
Study 20565154 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management (CM)
Number of subjects: 193
Study 20565154 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with frequent urine toxicology monitoring
Number of subjects: 193
Study 18460957 — intervention group
Group type: EXPERIMENTAL
Intervention: Quick Read (QR)-CRP test
Number of subjects: 50
Study 18460957 — intervention group
Group type: COMPARATOR
Intervention: Absolute neutrophil count
Number of subjects: 50
Study 18460957 — intervention group
Group type: COMPARATOR
Intervention: White blood cell count
Number of subjects: 50
Study 18460957 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of QR-CRP, absolute neutrophil count, and white blood cell count
Number of subjects: 50
Study 15989932 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal self‐ordered pointing test
Number of subjects: 24
Study 15989932 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐verbal self‐ordered pointing test
Number of subjects: 24
Study 15989932 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal span task
Number of subjects: 24
Study 15558389 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm-crank rehabilitation training program (6 weeks) in addition to traditional rehabilitation
Number of subjects: 14
Study 15558389 — intervention group
Group type: COMPARATOR
Intervention: Traditional rehabilitation only
Number of subjects: 14
Study 11772270 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth-based triple therapy monocapsule (Helicide) containing bismuth, tetracycline, and metronidazole.
Number of subjects: 0
Study 11772270 — intervention group
Group type: COMPARATOR
Intervention: Bismuth-based triple therapy (without the monocapsule) including bismuth, tetracycline, and metronidazole.
Number of subjects: 0
Study 9203211 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine free beta hCG
Number of subjects: 416
Study 9203211 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine beta core
Number of subjects: 416
Study 9203211 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine total oestriol
Number of subjects: 416
Study 9203211 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal serum free beta hCG
Number of subjects: 416
Study 9203211 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuchal translucency
Number of subjects: 416
Study 9203211 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine total oestriol combined with maternal age
Number of subjects: 416
Study 9203211 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine beta core combined with maternal age
Number of subjects: 416
Study 9203211 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine free beta hCG combined with maternal age
Number of subjects: 416
Study 9203211 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal serum free beta hCG combined with maternal age
Number of subjects: 416
Study 9203211 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine total oestriol combined with nuchal translucency
Number of subjects: 416
Study 9203211 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine beta core combined with nuchal translucency
Number of subjects: 416
Study 9203211 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine free beta hCG combined with nuchal translucency
Number of subjects: 416
Study 9203211 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal serum free beta hCG combined with nuchal translucency
Number of subjects: 416
Study 7966807 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex ultrasonography
Number of subjects: 20
Study 7966807 — intervention group
Group type: EXPERIMENTAL
Intervention: Air plethysmography (APG)
Number of subjects: 20
Study 7966807 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoplethysmography (PPG)
Number of subjects: 20
Study 7966807 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous filling index
Number of subjects: 20
Study 7966807 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual volume fraction
Number of subjects: 20
Study 7966807 — intervention group
Group type: EXPERIMENTAL
Intervention: Kappa coefficient of agreement
Number of subjects: 20
Study 3325395 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg b.i.d.
Number of subjects: 600
Study 3325395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 29720161 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program for ASHAs on hypertension management
Number of subjects: 15
Study 29720161 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based education support groups led by ASHAs
Number of subjects: 15
Study 29720161 — intervention group
Group type: EXPERIMENTAL
Intervention: Training materials for ASHAs
Number of subjects: 15
Study 27884124 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS intervention (ten messages delivered three times over two weeks)
Number of subjects: 350
Study 27884124 — intervention group
Group type: EXPERIMENTAL
Intervention: IS intervention (one session immediately after pretest)
Number of subjects: 350
Study 27884124 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined SMS and IS intervention
Number of subjects: 350
Study 27884124 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 350
Study 25084108 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanofilled resin composite (Filtek Z350, 3M ESPE)
Number of subjects: 41
Study 25084108 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanohybrid resin composite (Esthet‐X, Dentsply)
Number of subjects: 41
Study 25084108 — intervention group
Group type: COMPARATOR
Intervention: Microhybrid resin composite (Filtek Z250, 3M ESPE)
Number of subjects: 41
Study 25084108 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of three composites after 54 months
Number of subjects: 41
Study 25084108 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall performance of materials
Number of subjects: 41
Study 25084108 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary caries and postoperative sensitivity
Number of subjects: 41
Study 25084108 — intervention group
Group type: EXPERIMENTAL
Intervention: Marginal adaptation
Number of subjects: 41
Study 22321056 — intervention group
Group type: COMPARATOR
Intervention: PXG group
Number of subjects: 53
Study 22321056 — intervention group
Group type: COMPARATOR
Intervention: PXS group
Number of subjects: 53
Study 22321056 — intervention group
Group type: COMPARATOR
Intervention: PXS, PXG, and control groups
Number of subjects: 53
Study 20806180 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp 30
Number of subjects: 478
Study 18762707 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus pravastatin
Number of subjects: 0
Study 18762707 — intervention group
Group type: COMPARATOR
Intervention: Diet
Number of subjects: 0
Study 16381993 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment for 9 months
Number of subjects: 30
Study 16381993 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 30
Study 14658975 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine
Number of subjects: 40
Study 14658975 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 40
Study 10799368 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated soy protein (ISP) 50:0 g
Number of subjects: 81
Study 10799368 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated soy protein (ISP) 40:10 g
Number of subjects: 81
Study 10799368 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated soy protein (ISP) 30:20 g
Number of subjects: 81